Two groups release studies based on same insurance claims database, finding nearly 11% rate of serious adverse reactions to ...

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the ...

Pfizer recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company ...

As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13 ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in the Philippines, coinciding with its 175th-year global milestone.

Pfizer isn't a great pick for growth investors, although its growth prospects are better than some might think. The stock is a good fit for value investors, though, with its low forward earnings ...

Pharmaceutical giant Pfizer (NYSE: PFE) was a big winner during the COVID-19 pandemic. Its vaccine and antiviral pill generated billions of dollars in sales. However, that revenue source has ...

Pfizer has a deep lineup and pipeline, generates consistent results, and pays dividends. Moderna is on the verge of key approvals and has exciting pipeline candidates in the works. One of these ...

In GSK’s suit against Pfizer, the British pharma was seeking monetary damages or royalties and potentially a permanent injunction on the commercialization of Pfizer’s RSV vaccine in the U.S.

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials, including monitoring ctDNA as a therapy response marker Pfizer gains access to Guardant’s testing ...